Anatomy hub
Foot & Ankle: Options and What the Evidence Actually Shows
Plantar fasciitis and Achilles tendinopathy are high-volume soft-tissue problems. Regenerative injectates are adjuncts after load and rehab.
Anatomy and clinical context
The plantar fascia and Achilles tendon take repetitive load. Most pathology is degenerative tendinopathy or fasciopathy, not acute tear.
Shockwave, orthotics, and progressive loading are mainstays. Injections and surgery follow for refractory disease.
Illustration of the foot and ankle
The standard-of-care ladder
Conservative care first, then injections, then surgery when indicated. Cell therapy belongs in that conversation — not above it.
- Step 1
Conservative care
Load modification, stretching, orthotics, night splints, and progressive loading programs.
- Step 2
Injections
Corticosteroid (fascia, selective), PRP, and other orthobiologics in refractory cases.
- Step 3
Surgery
Fasciotomy, tendon debridement, or reconstruction when nonoperative care fails.
Where cell therapy fits
Foot and ankle orthobiologic data is condition-specific and often PRP-centered. Cell banking is secondary here unless you are banking for a broader longevity plan.
- Plantar fasciitis and Achilles tendinopathy usually respond to mechanical care first.
- PRP evidence is mixed-to-promising depending on protocol — ask for the study your clinic cites.
- MSC banking remains relevant if you want younger cells available for other sites later.
Selected citations
Shapiro 2017
Shapiro et al. · AJSM (2017)
BMAC vs saline in the same patient's other knee — no difference on primary outcomes.
Why dose and donor age change the picture
The trials that disappoint used unexpanded cells from older donors.
The ones that work used expanded cells at therapeutic dose. Dose is the variable — and dose is what expansion buys you. Potency is what your age buys you.
- 1
Cells work at dose.
A same-day draw yields a small, uncounted, unexpanded fraction. Expansion turns one draw into many doses.
- 2
Potency is age-dependent, and it is a one-way door.
Your MSCs at 35 are not your MSCs at 55. Banking is the only mechanism that makes 35-year-old cells available to a 55-year-old.
- 3
Expansion is what makes the bank a supply, not a souvenir.
Bank once, expand repeatedly, across a treatment course rather than a single shot. Culture expansion for Forever Labs members is rolling out — starting with selected states as our Florida cGMP lab comes online.
- 4
The provider decides what happens next.
We supply cells; they practice medicine. Forever Labs does not treat conditions — your physician owns the clinical relationship.
Two next steps — equal weight
Forever Labs does not treat conditions. Your physician owns the clinical relationship. We bank cells and, as expansion rolls out, help make dose possible.